Oncology Drug Report Featuring Herceptin & Trastuzumab: 2006-2015 Analysis & 2016-2021 Expectations - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Oncology Drug Report - Herceptin - Trastuzumab - 2006-2015 Analysis; 2016-2021 Expectations" report to their offering.

Herceptin (trastuzumab): 2006-2015 analysis; 2016-2021 expectations is a comprehensive report on the second-largest oncology drug by 2015 sales.

Herceptin falls in the monoclonal antibody, HER2 inhibitor, class of drugs belonging to the targeted therapy. It is indicated for the treatment of metastatic breast cancer and metastatic gastric cancer.

The report provides basic information about the drug, covering all details such as brand name, date of approvals, mechanism of action, molecular structure, route of administration, etc. It has an interesting infographic description of the approval timeline and contains an event tracker, which covers all the major events around the drug, news about Herceptin, information on biosimilar filings, number of clinical trials (by year and by phase), clinical study data about Herceptin and other competing drugs and so on.

The report gives an analysis of the historical annual sales (from 2006-2015), historical quarterly sales (Q1-2013 to Q3-2016), cumulative sales till date, Q3-2016 update and sales expectations (from 2016-2021). The analysis broadly indicates that the drug has given a successful decade and sales will be stable until 2016, after which they are likely to fall. Cumulatively, Herceptin has seen sales of USD 65 bn since its launch.

Key Topics Covered:

1. Basic Information

2. Approval timeline infographic (1998-2014)

4. Historical annual sales analysis (2006-2015, 2016E)

5. Historical quarterly sales analysis (Q1-2013 to Q3-2016)

6. Historical cumulative sales (1998 to Q3-2016)

7. Q3-2016 update

8. Sales expectations (2016E-2021E)

9. Biosimilar filings

10. List of key approved drugs in breast cancer

11. List of key approved drugs in gastric cancer

12. Event tracker

13. Clinical trials of Herceptin (US)

14. News around Herceptin

15. Annexure

Companies Mentioned

  • Allergan
  • Amgen
  • AstraZeneca
  • Bio Farma Indonesia
  • BioXpress Therapeutics
  • Celltrion
  • Dong-A ST
  • Dr Reddys Laboratories
  • Eisai
  • Eli Lilly
  • Gedeon Richter
  • Genor Biopharm
  • Glycotope
  • Hanwha Biologics
  • Harvest Moon Pharmaceuticals
  • Hetero Drugs
  • ISU Abxis
  • International Biotech Center Generium
  • Kyowa Hakko Kirin
  • Mabion
  • Mylan
  • Novartis
  • Oncobiologics
  • Paras Biopharmaceuticals
  • Pfizer
  • PlantForm Corporation
  • Polpharma
  • Reliance Life Sciences
  • Roche
  • STC Biologics
  • Samsung Bioepis
  • Sanofi
  • Shanghai CP Guojian Pharmaceutical
  • Shanghai Henlius Biotech
  • mAbxience

For more information about this report visit http://www.researchandmarkets.com/research/qnz429/oncology_drug

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs , Lung Cancer Drugs , Breast Cancer Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs , Lung Cancer Drugs , Breast Cancer Drugs